What is the BMS 927711?

BMS 927711 is , while it's Molecular Formula is C28H28F2N6O3. Used in Pharmaceutical Industry: BMS 927711 is used as a drug compound for the acute treatment of migraine with or without aura in adults. It works by selectively blocking the human 5-HT1F receptor, which helps to alleviate migraine symptoms. Used in Migraine Treatment: BMS 927711 is used as a migraine treatment for providing relief from pain and the most bothersome symptoms associated with migraine attacks. In clinical trials, a single dose of BMS 927711 has shown superiority over placebo in achieving freedom from pain and freedom from the most bothersome symptom at 2 hours post-dose.

What is the CAS number for BMS 927711?

The CAS number of BMS 927711 is 1289023-67-1.

What is BMS 927711 (1289023-67-1) used for?

Rimegepant (Nurtec ODT)(FDA approved in February 2020) is an ODT available in a single strength of 75 mg for the acute treatment of migraine with or without aura in adults.No more than 75 mg should be taken in a 24-hour period. while there are no contraindications，concomitant administration with CYP3A4 inhibitors should be avoided.The most common adverse reaction is nausea, occurring in few patients (rimegepant PI, 2020). In clinical trials, a single 75-mg dose of rimegepant demonstrated superiority over placebo with regard to freedom from pain (21% in the rimegepant group vs.11% in the placebo group) and freedom from the most bothersome symptom (35% vs. 27%) at 2 hours post dose (Croop et al., 2019). Rimegepant is not approved for migraine prevention, although it is presently in late-stage clinical trials assessing it for that indication(NCT03732638,2020).

What is the BMS 927711?

BMS 927711 is , while it's Molecular Formula is C28H28F2N6O3. Used in Pharmaceutical Industry: BMS 927711 is used as a drug compound for the acute treatment of migraine with or without aura in adults. It works by selectively blocking the human 5-HT1F receptor, which helps to alleviate migraine symptoms. Used in Migraine Treatment: BMS 927711 is used as a migraine treatment for providing relief from pain and the most bothersome symptoms associated with migraine attacks. In clinical trials, a single dose of BMS 927711 has shown superiority over placebo in achieving freedom from pain and freedom from the most bothersome symptom at 2 hours post-dose.

What is the CAS number for BMS 927711?

The CAS number of BMS 927711 is 1289023-67-1.

What is BMS 927711 (1289023-67-1) used for?

Rimegepant (Nurtec ODT)(FDA approved in February 2020) is an ODT available in a single strength of 75 mg for the acute treatment of migraine with or without aura in adults.No more than 75 mg should be taken in a 24-hour period. while there are no contraindications，concomitant administration with CYP3A4 inhibitors should be avoided.The most common adverse reaction is nausea, occurring in few patients (rimegepant PI, 2020). In clinical trials, a single 75-mg dose of rimegepant demonstrated superiority over placebo with regard to freedom from pain (21% in the rimegepant group vs.11% in the placebo group) and freedom from the most bothersome symptom (35% vs. 27%) at 2 hours post dose (Croop et al., 2019). Rimegepant is not approved for migraine prevention, although it is presently in late-stage clinical trials assessing it for that indication(NCT03732638,2020).

Product classification

Contact us

Tel：+86-0533-2185556
Fax：+86-0533-2185556
Phone：WhatsApp: +86 15965530500
Website：https://www.shandonghangyubiotech.com
Email：admin@hangyubiotech.com
Address：Room 2516, Dingcheng Building, Beijing Road, Zhangdian District, Zibo City, Shandong Province

1289023-67-1

Product Name:Rimegepant
Molecular Formula:C28H28F2N6O3
Molecular Weight:534.566

Inquiry

Product Details

Purity:99%

Bulk supply high purity Rimegepant 1289023-67-1, Paid sample available

Molecular Formula:C28H28F2N6O3
Molecular Weight:534.566
PKA:12.03±0.20(Predicted)
PSA：119.39000
Density:1.45±0.1 g/cm3(Predicted)
LogP:5.54050

1289023-67-1 Relevant articles

Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern

-

Paragraph 0158; 0159, (2015/01/18)

The invention relates to a packaging com...

N-(5S,6S,9R)-5-AMINO-6-(2,3-DIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA[B]PYRIDIN-9-YL-4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-YL)PIPERIDINE-1-CARBOXYLATE SALT

-

, (2013/09/12)

Disclosed is a hemisulfate salt of Compo...

PROCESS FOR THE PREPARATION OF CYCLOHEPTAPYRIDINE CGRP RECEPTOR ANTAGONISTS

-

Page/Page column 12-13, (2012/05/04)

The disclosure generally relates to a pr...

Discovery of (5S,6S,9R)-5-aqmino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro- 5H-cyclohepta[b]pyridin-9-yl4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxylate (BMS-927711): An oral Calcitonin Gene-Related Peptide (CGRP) antagonist in cinical trials for treating migraine

Luo, Guanglin,Chen, Ling,Conway, Charles M.,Denton, Rex,Keavy, Deborah,Signor, Laura,Kostich, Walter,Lentz, Kimberley A.,Santone, Kenneth S.,Schartman, Richard,Browning, Marc,Tong, Gary,Houston, John G.,Dubowchik, Gene M.,MacOr, John E.

, p. 10644 - 10651 (2013/02/23)

Calcitonin gene-related peptide (CGRP) r...

1289023-67-1 Process route

: 1289023-63-7
(5S,6S,9R)-5-azido-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo-[4,5-b]pyridin-1-yl)piperidine-1-carboxylate

: 1289023-67-1
BMS-927711

Conditions

Conditions	Yield
(5S,6S,9R)-5-azido-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo-[4,5-b]pyridin-1-yl)piperidine-1-carboxylate; With trimethylphosphane; In tetrahydrofuran; toluene; at 20 ℃; for 2h; With water; In tetrahydrofuran; toluene; for 3h;	85%
With trimethylphosphane; In tetrahydrofuran; toluene; at 20 ℃; for 2h; Inert atmosphere;	85%
With trimethylphosphane; In tetrahydrofuran; toluene; at 20 ℃; for 2h;	85%
Multi-step reaction with 2 steps 1: tetrahydrofuran; toluene / 2 h / 20 °C 2: water / tetrahydrofuran; toluene / 3 h / 20 °C With water; In tetrahydrofuran; toluene;

: 1-(1-(1H-imidazole-1-carbonyl)piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one

: (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol dihydrochloride

: 1289023-67-1
BMS-927711

Conditions

Conditions	Yield
(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol dihydrochloride; With water; sodium carbonate; sodium chloride; for 0.5h; 1-(1-(1H-imidazole-1-carbonyl)piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one; With potassium 2,2-dimethyl-1-propanolate; In tetrahydrofuran; at 20 ℃; With citric acid; sodium chloride; In tetrahydrofuran; water;	78.3%
With potassium tert-butylate; In tetrahydrofuran;

1289023-67-1 Upstream products

1190363-50-8
(5S,6S,9R)-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]-pyridin-5-ol
1289024-04-9
(5R,6S,9R)-5-chloro-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
1289024-05-0
(5S,6S,9R)-5-azido-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine
1289024-06-1
(5S,6S,9R)-5-azido-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol

1289023-67-1 Downstream products

1289023-77-3
(5S,6S,9R)-6-(2,3-difluorophenyl)-5-(dimethylamino)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
1289023-74-0
(5S,6S,9R)-6-(2,3-difluorophenyl)-5-(methylamino)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate

Relevant Products

2-METHYL-4-(TRIFLUOROMETHYL)-1,3-THIAZOLE-5-CARBOXYLIC ACID
CAS：117724-63-7
PD 0325901
CAS：391210-10-9
9H-Carbazole, 9,9'-(2-bromo-1,3-phenylene)bis-
CAS：2227146-17-8
Mitochonic acid 5
CAS：1354707-41-7